Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy

Seminars in Nephrology

Volumn 24, Issue 3, 2004, Pages 244-255

  Hotta, Osamu ^a  

^a Sendai Shakaihoken Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; DRUG PULSE THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TONSILLECTOMY;

EID: 2542438899     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2004.01.005     Document Type: Article

References (106)

1. D'Amico G, Imbasciati E, Barbiano D, et al: Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine 64:49-60, 1985
2. Levy M, Berger J: Worldwide perspective of IgA nephropathy. Am J Kidney Dis 12:340-347, 1988
3. Berger J, Hinglais N: Les depots intercapillaries d'IgA-IgG. J Urol Nephrol 74:694-695, 1968
4. Koyama A, Igarashi M, Kobayashi M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Disease. Am J Kidney Dis 29:526-532, 1997
5. Galla JH: IgA nephropathy. Kidney Int 47:377-387, 1995
6. Kobayashi Y, Sano T, Hashizume K, et al: Long-term prognosis of 366 IgA nephropathy patients. Nephrology 7 (suppl):A97, 2002
7. Julian BA: Treatment of IgA nephropathy. Semin Nephrol 20:277-285, 2000
8. Glassock RJ: The treatment of IgA nephropathy: Status at the end of the millennium. J Nephrol 12:288-296, 1999
9. Locatelli F, Pozzi C, Del Vecchio L, et al: New therapeutic approaches in primary IgA nephropathy. Adv Nephrol 29:73-91, 1999
10. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 347:738-748, 2002
11. Szeto CC, Lai FMM, To KF, et al: The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 110:434-437, 2001
12. Hotta O, Miyazaki M, Furuta T, et al: Tonsillectomy and steroid pulse therapy significantly impact in patients with IgA nephropathy. Am. J. Kidney Dis 38:736-742, 2001
13. Hotta O, Furuta T, Chiba S, et al: Regression of IgA nephropathy: A repeat biopsy study. Am J Kidney Dis 39:493-502, 2002
14. Hotta O, Taguma Y, Kurosawa K, et al: Predictive value of small crescents in IgA nephropathy: Analysis of four patients showing a deteriorated renal function during a long follow-up period. Clin Nephrol 40:125-130, 1993
15. Ferrario F, Napodano P, Rastaldi MP, et al: Capillaritis in IgA nephropathy. Contrib Nephrol 111:8-12, 1995
16. Neuringer JR, Brenner BM: Hemodynamic theory of progressive renal disease: A 10-year update in brief review. Am J Kidney Dis 22:98-104, 1993
17. Eddy A: Molecular insights into renal fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
18. Johnson RJ, Herrera-Acosta J, Schreiner GF, et al: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923, 2002
19. Maschio G, Alberti D, Janin G, et al: Effect of angiotensin converting enzyme inhibitor benazapril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
20. Apperloo AJ, de Zeeuw D, de Jong PE: A short-term anti-hypertensive treatment induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793-797, 1997
21. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrogia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1587-1863, 1997
22. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
23. Brenner BM, Cooper ME, Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
24. Donadio JV Jr, Bergstrath EJ, Offord KP, et al: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331:1194-1199, 1994
25. Pedrini MT, Levey AS, Lau J, et al: The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal disease: a meta-analysis. Ann Intern Med 124:627-632, 1996
26. Berger J, Yaneva H, Nabarra B, et al: Recurrence of mesangial IgA deposition of IgA after renal transplantation. Kidney Int 7:232-241, 1975
27. Odum J, Peh CA, Clarkson AR, et al: Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 9:309-312, 1994
28. Wang AYM, MacMoune Lai F, Wai-Yin Yu A, et al: Recurrent IgA nephropathy in renal transplant allograft. Am J Kidney Dis 38:588-596, 2001
29. Sanfilippo F, Croker BP, Bollinger RR: Fate of four cadaveric renal allografts with mesangial IgA deposits. Transplantation 33:370-376, 1982
30. Silva FG, Chander P, Pirani CL, et al: Disappearance of mesangial IgA deposits after allograft transplantation. Transplantation 33:214-216, 1982
31. Suzuki S, Nakatomi Y, Sato H, et al: Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet 343:12-15, 1994
32. Drew PA, Nieuwhof WN, Clarkson AR, et al: Increased concentration of serum IgA antibodies to pneumococcal polysaccharides in patients with IgA nephropathy. Clin Exp Immunol 60:124-129, 1987
33. Cohen AJ, Rosenstein ED: IgA nephropathy associated with disseminated tuberculosis. Arch Intern Med 145:554-556, 1985
34. Tomino Y, Yagame M, Omata F, et al: A case of IgA nephropathy associated with adeno herpes simplex viruses. Nephron 47:258-261, 1987
35. Gregory MC, Hammond ME, Brewer ED: Renal deposition of cytomegalovirus antigen in immunoglobulin-A nephropathy. Lancet 2:11-14, 1988
36. Nagy J, Uj M, Szucs G, et al: Herpes virus antigens and antibodies in kidney biopsies and sera of IgA glomerulonephritic patients. Clin Nephrol 21:259-262, 1984
37. Sato M, Kojima H, Takayama K, et al: Glomerular deposition of food antigens in IgA nephropathy. Clin Exp Immunol 73:295-299, 1988
38. Coppo R, Basoco B, Rollino C, et al: Mediterranean diet and primary IgA nephropathy. Clin Nephrol 26:72-82, 1986
39. Czerkinsky C, Koopman WJ, Jackson S, et al: Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest 77:1931-1938, 1986
40. Sinico RA, Fornasieri A, Oreni N, et al: Polymeric IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger's disease). J Immunol 137:536-541, 1986
41. Ballardie FW, Brenchley PE, Williams S, et al: Autoimmunity in IgA nephropathy. Lancet 2:588-592, 1988
42. Wang MX, Walker RG, Kinkaid-Smith P: Clinicopathologic association of anti-endothelial cell antibodies in immunoglobulin A nephropathy and lupus nephritis. Am J Kidney Dis 22:378-386, 1993
43. Fu YX, Chaplin DD: Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 17:399-433, 1999
44. Sato Y, Hotta O, Taguma Y, et al: IgA nephropathy with poorly developed lymphoepithelial symbiosis of the palatine tonsils. Nephron 74:301-308, 1996
45. De Fijter JW, Eijgenraam JW, Braam CA, et al: Deficient IgA1 immune response to nasal cholera toxin subunit B in IgA nephropathy. Kidny Int 50:952-961, 1996
46. Roodnat JI, de Fijter JW, van Kooten C, et al: Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant 14:353-359, 1999
47. Feehally J, Allen AC: Pathogenesis of IgA nephropathy. Ann Med Interne (Paris) 150:91-98, 1999
48. Hiki Y, Odani H, Takahashi M, et al: Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59:1077-1085, 2001
49. Odani H, Hiki Y, Takahashi M, et al: Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry. Biochem Biophys Rec Commun 271:268-274, 2000
50. Tomana M, Novak J, Julian BA, et al: Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104:73-81, 1999
51. Ortmanns A, Ittel TH, Schnitzler N, et al: Remission of IgA nephropathy following treatment of cytomegalovirus infection with ganciclovir. Clin Nephrol 49:379-384, 1998
52. Kincaid-Smith P: Treatment of mesangial immunoglobulin A glomerulonephritis. Semin Nephrol 19:166-172, 1999
53. Hung KY, Chen MY, Yen TS, et al: Adult primary IgA nephropathy and common viral infections. J Infect 32:227-230, 1996
54. Xie Y, Nishi S, Ueno M, et al: The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 63:1861-1867, 2003
55. Masuda Y, Terazawa K, Kawakami S, et al: Clinical and immunological study of IgA nephropathy before and after tonsillectomy. Acta Otolaryngol 454:248-255, 1988 (suppl)
56. Bene MC, Hurault de Ligny B, Kessler M, et al: Tonsils in IgA nephropathy. Contrib Nephrol 104:153-161, 1993
57. Horie A, Nakamura I, Odani H, et al: MALDI-TOFMS analysis of structural alteration of O-glycosylated hinge peptides in serum IgA1 before and after tonsillectomy in IgA nephropathy [Abstract]. J Am Soc Nephrol 13:662A, 2002
58. Lakkis FG, Arakelov A, Konieczny BT, et al: Immunologic "ignorance" of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6:686-688, 2000
59. Chalasani G, Dai Z, Konieczny BT, et al: Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A 99:6175-6180, 2002
60. Andersson RA, Olaison G, Tysk C, et al: Appendectomy and protection against ulcerative colitis. N Engl J Med 344:808-814, 2001
61. Hotta O, Taguma Y, Sudo K, et al: Limitation of kidney biopsy in detecting crescentic lesions in IgA nephropathy. Nephron 65:472-473, 1993.
62. Tolkoff-Rubin NE, Cosimi AB, Fuller T, et al: IgA nephropathy in HLA-identical siblings. Transplantation 26:430-433, 1978
63. Sinniah R: Occurrence of mesangial IgA and IgM deposits in a control necropsy population. J Clin Pathol 36:276-279, 1983
64. Terasaki T, Sano M, Narita M, et al: Ultrastructural study of gaps of the glomerular basement membrane in IgA nephropathy. Am J Nephrol 6:443-449, 1986
65. Shigematsu H, Kobayashi Y, Tateno Y, et al: Ultrastructural glomerular loop abnormalities in IgA nephritis. Nephron 30:1-7, 1982
66. Kincaid-Smith P, Nicholls K: Mesangial IgA nephropathy. Am J Kidney Dis 3:90-102, 1983
67. Benett WM, Kincaid-Smith P: Macroscopic hematuria in mesangial, IgA nephropathy: Correlation with glomerular crescent and renal dysfunction. Kidney Int 23:393-400, 1983
68. Abe T, Kida H, Yoshimura M, et al: Participation of extracapillary lesions in progression of IgA nephropathy. Clin Nephrol 25:37-41, 1986
69. Hotta O, Yusa N, Ooyama M, et al: Detection of urinary macrophages expressing the CD16 (FcγRIII) molecule: A novel marker of acute inflammatory glomerular injury. Kidney Int 55:1927-1934, 1999
70. Hotta O, Yusa N, Kitamura H, et al: Urinary macrophages as activity markers of renal injury. Clin Chim Acta 297:123-133, 2000
71. Lagrue G, Sadreux T, Laurant J, et al: Is there a treatment of mesangial IgA nephropathy. Clin Nephrol 14:161, 1981
72. Sugiyama N: Clinicopathological study of the effectiveness of tonsillectomy in IgA nephropathy accompanied by chronic tonsillitis. Acta Otolaryngol 508:43-48, 1993 (suppl)
73. Iino Y, Ambe K, Kato Y, et al: Chronic tonsillitis and IgA nephropathy. Acta Otolaryngol 508:29-35, 1993 (suppl)
74. Tamura S, Masuda Y, Inokuchi I, et al: Effect and indication of for tonsillectomy in IgA nephropathy. Acta Otolaryngol 508:23-28, 1993
75. Akagi H, Nishizaki K, Hattori K, et al: Prognosis of tonsillectomy in patients with IgA nephropathy. Acta Otolaryngol 540 (suppl):64-66, 1999
76. Rasche FM, Schwarz A, Keller F: Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 51:147-152, 1999
77. Kataura A, Tsubota H: Clinical analysis of focus tonsil and related disease in Japan. Acta Otolaryngol 523 (suppl): 161-164, 1996
78. Ono T, Jono M, Kito M, et al: Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol 401 (suppl):12-16, 1983
79. Matsutani S, Hotta O: Urinalysis after tonsillectomy in IgA nephropathy [Abstract, in Japanese]. Jpn J Nephrol 43:205, 2001
80. Kobayashi Y, Fujii K, Hiki Y, et al: Steroid therapy in IgA nephropathy: A retrospective study in heavy proteinuric cases. Nephron 48:12-17, 1988
81. Kobayashi Y, Hiki Y, Kokubo T, et al: Steroid therapy during the early stage of progressive IgA nephropathy: A 10-year follow-up study. Nephron 72:237-242, 1996
82. Shoji T, Nakanishi I, Suzuki A, et al: Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35:194-201, 2000
83. Lai KN, Lai FM, Ho CP: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin Nephrol 26:174-180, 1986
84. Welch TR, Fryer C, Shely E, et al: Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121:474-477, 1992
85. Waldo B, Wyatt RJ, Kelly DR, et al: Treatment of IgA nephropathy in children: Efficacy of alternate-day prednisolone. Pedatr Nephrol 7:529-532, 1993
86. Katafuchi R, Ikeda K, Mizumasa T, et al: Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 41:972-983, 2003
87. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 14:649-683, 1996
88. Buttgereit F, Wehling M, Burmester GR: A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis Rheum 41:761-767, 1998
89. Migita K, Eguchi K, Kawabe Y, et al: Apoptosis of induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 63:583-587, 1997
90. Bronnegard M: Steroid receptor number: Individual variation and downregulation by treatment. Am J Respir Crit Care Med 154:S28-33, 1996
91. Sabir S, Werth VP: Pulse glucocorticoid. Inpatient Dermatol 18:437-445, 2000
92. Pozzi C, Bolasco PG, Gogazzi G, et al: Corticosteroids in IgA nephropathy: A randomized controlled trial. Lancet 353:883-887, 1999
93. Locatelli F, Pozzi C, Vecchio LD, et al: Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomized multicentre trial. J Nephrol 12:308-311, 1999
94. Tamura S, Ueki K, Ideura H, et al: Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 55:192-195, 2001
95. Yoshikawa N, Hiroshi I, Sakai T, et al: A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10:101-109, 1999
96. Ballardie FW, Roberts ISD: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142-148, 2002
97. Oshima S, Kubota T, Kawamura O, et al: Long-term follow-up of prednisolone and cyclophosphamide therapy in IgA nephropathy. Nephrology 5:A20-A21, 1999 (suppl)
98. Allison AC, Kowalski WJ, Muller CJ, et al: Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25:67-70, 1993
99. Novack R, Brick R, van der Woude FJ: Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349:774, 1997
100. Chen XM, Zhang YP, Qui Q, et al: Short-term effects of mycophenolate mofetil on IgA nephropathy [Abstract]. J Am Soc Nephrol 10:69A, 1999
101. Chen X, Chen Pu, Cai G, et al: A randomized control study of mycophenolate mofetil treatment in severe IgA nephropathy [Abstract]. J Am Soc Nephrol 13:14A, 2002
102. Nagaoka R, Kaneko K, Ohtani Y: Mizoribine treatment for childhood IgA nephropathy. Pediatr Int 44:217-223, 2002
103. Lai KN, Lai FM, Li PK, et al: Cyclosporin treatment of IgA nephropathy: A short term controlled trial. BMJ 295:1165-1168, 1987
104. Sato M, Hotta O, Tomioka S, et al: Cohort study of advanced IgA nephropathy: Efficacy and limitations of corticosteroids with tonsillectomy. Nephron 93:137-145, 2003
105. Pozzi C, Vecchio LD, Locatelli F: Can immunosuppressive therapy be useful in IgA nephropathy when the "point of no return" has already been exceeded? Nephron 92:699-701, 2002
106. Chauveau D, Droz D: Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 104:1-5, 1993